Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sales & Earnings

Set Alert for Sales & Earnings

Leaner Kabi Drives Higher Savings Goal For Fresenius, China ‘Soft’ In 2024

Fresenius Kabi insists there is a “business plan behind everything” as it divulged a higher cost savings goal for the end of next year, following a fruitful 2023. But queries over margins led the company to stress that it was combatting a variety of uncertainties, especially in China and for its burgeoning biosimilars unit.

Sales & Earnings Strategy

Biocon Eyes 'Foothold To Stronghold' For (b)Humira In US, Pauses RH-Insulin Program

Biocon sees some wins for biosimilar adalimumab in the US and signals more opportunities amid the slower than anticipated build-out for Humira rivals. Chinese competition looms for glargine, but the Indian company declares it “will be competitive if these folks launch.”

Biosimilars Strategy

Lupin Reports Near 300% Profit Growth Coupled With Launches

The Indian generics manufacturer has reported a nearly 300% year-on-year growth in profits in Q3, as it starts to see the impact of its Spiriva generic’s launch in the US.

Sales & Earnings Generic Drugs

Biogen’s Biosimilars Sales Rise, But Future Still Unknown

Biogen has yet again hinted about “strategic alternatives” for its biosimilars business albeit with no clear future plans, while its branded multiple sclerosis portfolio fights off generic and biosimilar competitors.

Biosimilars Strategy

Amgen’s Amjevita US Sales On The Rise, Oncology Biosimilars Still In Slump

It seems that the first US Humira biosimilar is recovering from the predicted slow uptake, but Amgen’s oncology biosimilars portfolio continues to deteriorate.

Biosimilars Sales & Earnings

No 'Constraining Situation' On Generic Vascepa API, Says Strides MD

Strides intends to keep US momentum going with Amneal-partnered generic Vascepa, where Hikma and Dr. Reddy’s have filed antitrust suits against Amarin over API supply. Meanwhile, the founder re-iterated ambitious goals set for Stelis and its CDMO business.

Strategy Ingredients

‘Stabilize’ Is The Message For Teva In North America As It Plots Return To Growth

“The value that generics bring to the healthcare industry, to the hospitals, to society is not reflected in the price that we can sell them at,” Teva told investors, as it outlined plans to mitigate erosion with a slate of big-ticket launches in the US.

Strategy Sales & Earnings

Cipla Points To Large GLP-1 India Opportunity Amid Speculation On Lilly Deal

Cipla refers to the transformational potential of GLP-1s in India, a market with 100m-plus diabetics and rising obesity, amid plans for oral semaglutide and speculation on partnering possibilities. A recalibration in the firm’s specialty products thrust is also seen. 

Strategy Sales & Earnings

Krka To Plant Its Flag In India With Laurus Labs JV

Delivering record annual sales and profits according to preliminary financial results, Slovenia’s Krka will soon look to set up shop in India via a new company established with local big player Laurus Labs.

Deals Strategy

A $10bn Target: Stelara Sales Break Barrier Ahead Of Biosimilar Launches

With competition to Stelara due to kick in midway through 2024, the brand now represents a $10bn+ target for biosimilars, according to the latest figures from J&J.

Sales & Earnings Biosimilars

Towa Buys Out Kamata Following Facility Expansion And Guidance Raise

Japanese generics firm Towa has acquired Kamata as a wholly owned subsidiary, in order to increase soft capsule manufacturing capacity for its Sunsho segment. The firm has also announced that it has completed expansion works at its Yamagata plant and made a moderate revision to its financial forecast.

Generic Drugs Strategy

Krka Targets Sales Growth Under New Five-Year Plan – With EBITDA Margin To Regress

Presenting nine-month financial results, Krka disclosed a new slate of strategic objectives stretching out until 2028 – including a tacit admission that its current EBITDA margin may not be sustainable.

Sales & Earnings Strategy

Numerous US Approvals Received By Lupin Following 278% Quarterly Profits Raise

Lupin has announced a number of drug approvals in the US, as well as a biosimilar partnership in the Middle East and the launch of a novel fixed-dose triple combination drug in its native Indian market.

Generic Drugs Approvals

Merck As Anchor, Scale As Lever, Aurobindo Looks To Spar With Lonza, WuXi Group

Starting off with MSD as an anchor partner, Aurobindo plans to eventually spar with the likes of WuXi and Lonza while building scale for its biologics CDMO business. Meanwhile, EMA approval for a greenfield project in China and an US FDA nod for Ryzneuta, licensed from Yifan’s Evive Biotech, signal a boost.

Strategy Sales & Earnings

Glenmark Seeks To Revive US Momentum After Earnings 'Aberration'

Glenmark hopes complex and respiratory products including a potential filing for generic Flovent pMDI can restore some lost sheen of its US business going forward, but a compliance comeback for its Monroe site may be pivotal to deliver material gains.

Strategy Sales & Earnings

Formycon Submits Eylea Biosimilar For European Approval Following Strong Q3

Formycon has submitted its aflibercept candidate for European Medicines Agency consideration, following an incredibly strong Q3 which has put the company on track for a promising future.

Biosimilars Europe